Results 101 to 110 of about 17,265 (196)

Transcatheter arterial chemoembolization combined with stereotactic body radiation therapy versus transcatheter arterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis. [PDF]

Front Oncol
Zeng D, Liu X, Zhang H, Zheng Y.
europepmc   +1 more source

Editorial: Hepatocellular carcinoma: from bench to bedside. [PDF]

Front Genet
İşcan E, Koenig AB, Wu X.
europepmc   +1 more source

Advancing risk stratification in intermediate-stage hepatocellular carcinoma undergoing transarterial chemoembolization: the promise of the NTAA model. [PDF]

Hepatobiliary Surg Nutr
Kobus Z, Yarmohammadi H.
europepmc   +1 more source

Comparison of the efficacy of transarterial chemoembolization combined with different molecular targeted agents and/or immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a systematic review and network meta-analysis. [PDF]

J Gastrointest Oncol
Long JY, Wang XH, Li YR, Huang SR, Li ZJ, Luo Y.   +5 more
europepmc   +1 more source

Efficacy of lenvatinib combined with sintilimab and transcatheter arterial chemoembolization in conversion therapy for unresectable hepatocellular carcinoma. [PDF]

Pak J Med Sci
Long J, Zheng J, Chen S, Ou P, Lu X.
europepmc   +1 more source

Impact of TACE combined with targeted and immune therapy on liver function and prognosis in unresectable hepatocellular carcinoma patients: the significance of baseline albumin-bilirubin grade. [PDF]

Ther Adv Med Oncol
Guo Y, Liu X, Sun B, Pu F, Li X, Zheng C, Kan X, Yang F.   +7 more
europepmc   +1 more source

Efficacy and safety of local treatments combined with targeted therapy and immunotherapy versus targeted therapy plus immunotherapy alone in hepatocellular carcinoma: A meta-analysis. [PDF]

Medicine (Baltimore)
Zhang S, Tang Y, Mao X, Sheng T.
europepmc   +1 more source

Safety and efficacy of drug-eluting beads versus conventional bronchial arterial chemoembolization for lung cancer: a systematic review and meta-analysis. [PDF]

Front Oncol
Gong Z, Liu Y, Song Y, Li X, Tian Y, Li J, Qi C.   +6 more
europepmc   +1 more source

Analysis of risk factors for post-transarterial chemoembolization syndrome in patients with liver cancer: a systematic review protocol. [PDF]

Syst Rev
Yang L, Huang S, Sheng X, Xu Q, Ding J.
europepmc   +1 more source

Transarterial chemoembolization combined with PD-1 inhibitors for unresectable hepatocellular carcinoma: efficacy and hepatic safety at 4-week versus 6-week treatment intervals. [PDF]

Am J Transl Res
Tian T, Wang Y, Guo W.
europepmc   +1 more source